244 related articles for article (PubMed ID: 8996519)
1. Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
Yamazaki K; Isobe H; Hanada T; Betsuyaku T; Hasegawa A; Hizawa N; Ogura S; Kawakami Y
Cancer Chemother Pharmacol; 1997; 39(3):192-8. PubMed ID: 8996519
[TBL] [Abstract][Full Text] [Related]
2. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.
Kasahara K; Fujiwara Y; Sugimoto Y; Nishio K; Tamura T; Matsuda T; Saijo N
J Natl Cancer Inst; 1992 Jan; 84(2):113-8. PubMed ID: 1310509
[TBL] [Abstract][Full Text] [Related]
3. Quantitative immunocytochemical assays of topoisomerase II in lung adenocarcinoma cell lines. Correlation to topoisomerase II alpha content and topoisomerase II catalytic activity.
Yamazaki K; Isobe H; Hanada T; Sukoh N; Ogura S; Kawakami Y
Acta Oncol; 1996; 35(4):417-23. PubMed ID: 8695154
[TBL] [Abstract][Full Text] [Related]
4. Reduced expression of DNA topoisomerase II confers resistance to etoposide (VP-16) in small cell lung cancer cell lines established from a refractory tumor of a patient and by in vitro selection.
Andoh T; Nishizawa M; Hida T; Ariyoshi Y; Takahashi T; Ueda R
Oncol Res; 1996; 8(6):229-38. PubMed ID: 8895198
[TBL] [Abstract][Full Text] [Related]
5. Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase II alpha.
Kuriyama M; Tsutsui K; Tsutsui K; Ono Y; Tamiya T; Matsumoto K; Furuta T; Ohmoto T
Neurol Med Chir (Tokyo); 1997 Sep; 37(9):655-61; discussion 661-2. PubMed ID: 9330528
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H
Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028
[TBL] [Abstract][Full Text] [Related]
7. Comparison of DNA topoisomerase II alpha expression in small cell and nonsmall cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response.
Guinee DG; Holden JA; Benfield JR; Woodward ML; Przygodzki RM; Fishback NF; Koss MN; Travis WD
Cancer; 1996 Aug; 78(4):729-35. PubMed ID: 8756364
[TBL] [Abstract][Full Text] [Related]
8. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
10. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
11. Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors.
Binaschi M; Capranico G; De Isabella P; Mariani M; Supino R; Tinelli S; Zunino F
Int J Cancer; 1990 Feb; 45(2):347-52. PubMed ID: 2154411
[TBL] [Abstract][Full Text] [Related]
12. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
Giaccone G; Gazdar AF; Beck H; Zunino F; Capranico G
Cancer Res; 1992 Apr; 52(7):1666-74. PubMed ID: 1312895
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
14. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells.
Montaudon D; Pourquier P; Denois F; de Tinguy-Moreaud E; Lagarde P; Robert J
Eur J Biochem; 1997 Apr; 245(2):307-15. PubMed ID: 9151958
[TBL] [Abstract][Full Text] [Related]
15. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
16. Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization.
Wessel I; Jensen PB; Falck J; Mirski SE; Cole SP; Sehested M
Cancer Res; 1997 Oct; 57(20):4451-4. PubMed ID: 9377550
[TBL] [Abstract][Full Text] [Related]
17. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
18. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
[TBL] [Abstract][Full Text] [Related]
20. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16.
Mirski SE; Evans CD; Almquist KC; Slovak ML; Cole SP
Cancer Res; 1993 Oct; 53(20):4866-73. PubMed ID: 8104687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
